Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.87
- Piotroski Score 3.00
- Grade Market Outperform
- Symbol (ATHA)
- Company Athira Pharma, Inc.
- Price $0.49
- Changes Percentage (-3.2%)
- Change -$0.02
- Day Low $0.49
- Day High $0.52
- Year High $4.30
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $18.00
- High Stock Price Target $33.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.05
- Trailing P/E Ratio -0.84
- Forward P/E Ratio -0.84
- P/E Growth -0.84
- Net Income $-117,672,000
Income Statement
Quarterly
Annual
Latest News of ATHA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
In 'Agatha All Along,' Joe Locke Works Like a Charm
Joe Locke, known for his role in "Heartstopper," is set to join the Marvel universe. Locke's journey from early rejection to Netflix stardom showcases his resilience and talent....
By The New York Times | 1 day ago -
Warren Buffett Has Nearly 50% of Berkshire Hathaway's Investable Portfolio in 1 Incredibly Safe Bet
Warren Buffett's investing prowess is evident in Berkshire Hathaway's stellar performance over 58 years. He has shifted investments to Treasury bills, holding nearly 50% of the portfolio in them, anti...
By Yahoo! Finance | 1 day ago -
Patriots' Jonathan Jones looking for answers after controversial pass interference vs. Seahawks
Jonathan Jones seeks clarification from officials and the NFL regarding a disputed pass interference call in the Patriots' Week 2 loss to the Seahawks. Seattle's Tyler Lockett also indicated it was no...
By CBS News | 1 day ago
